BNP Paribas Financial Markets
CRBP icon

BNP Paribas Financial Markets’s Corbus Pharmaceuticals CRBP Stock Holding History

BNP Paribas Financial Markets’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$733K Buy
78,120
+67,631
+645% +$640K ﹤0.01% 3523
2026
Q1 		$98.5K Buy
10,489
+10,450
+26,795% +$88K ﹤0.01% 4385
2025
Q4 		$317 Sell
39
-475
-92% -$5.86K ﹤0.01% 5521
2025
Q3 		$6.5K Sell
514
-1,742
-77% -$16.6K ﹤0.01% 5069
2025
Q2 		$15.6K Sell
2,256
-1,396
-38% -$10.1K ﹤0.01% 4708
2025
Q1 		$19.4K Sell
3,652
-23,731
-87% -$209K ﹤0.01% 4544
2024
Q4 		$323K Buy
+27,383
New +$459K ﹤0.01% 3582
2023
Q1 		– Sell
-3
Closed -$11 – 3890
2022
Q4 		$11 Hold
3
– – ﹤0.01% 4003
2022
Q3 		$16 Hold
3
– – ﹤0.01% 4695
2022
Q2 		$25 Hold
3
– – ﹤0.01% 4053
2022
Q1 		$53 Sell
3
-7
-70% -$93 ﹤0.01% 4105
2021
Q4 		$191 Sell
10
-98
-91% -$2.65K ﹤0.01% 4149
2021
Q3 		$3.29K Sell
108
-15
-12% -$592 ﹤0.01% 3746
2021
Q2 		$6.74K Sell
123
-226
-65% -$12.5K ﹤0.01% 3784
2021
Q1 		$20.6K Sell
349
-2,040
-85% -$134K ﹤0.01% 3754
2020
Q4 		$89.6K Buy
2,389
+1,737
+266% +$64.9K ﹤0.01% 3266
2020
Q3 		$35.2K Buy
652
+414
+174% +$75K ﹤0.01% 3622
2020
Q2 		$59.8K Sell
238
-398
-63% -$80.4K ﹤0.01% 2963
2020
Q1 		$100K Buy
636
+397
+166% +$67.1K ﹤0.01% 3209
2019
Q4 		$39.1K Sell
239
-68
-22% -$10.1K ﹤0.01% 3773
2019
Q3 		$44.9K Buy
307
+98
+47% +$17.1K ﹤0.01% 3537
2019
Q2 		$43.5K Sell
209
-180
-46% -$38.5K ﹤0.01% 3505
2019
Q1 		$81.2K Buy
389
+388
+38,800% +$85.6K ﹤0.01% 3247
2018
Q4 		$93 Sell
1
-48
-98% -$9.58K ﹤0.01% 4190
2018
Q3 		$11.2K Hold
49
– – ﹤0.01% 3677
2018
Q2 		$7.47K Sell
49
-297
-86% -$54K ﹤0.01% 3919
2018
Q1 		$63.3K Sell
346
-21
-6% -$4.72K ﹤0.01% 3429
2017
Q4 		$78.1K Buy
367
+223
+155% +$47.7K ﹤0.01% 3438
2017
Q3 		$30.9K Sell
144
-11
-7% -$2.15K ﹤0.01% 3383
2017
Q2 		$29.2K Buy
+155
New +$30.4K ﹤0.01% 3453

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BNP Paribas Financial Markets's CRBP Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Corbus Pharmaceuticals (CRBP) stake by 645% in Q2 2026, buying an estimated $640K and bringing the position to 78,120 shares worth $733K. The position accounts for ﹤0.01% of the portfolio, ranked #3523.

BNP Paribas Financial Markets first reported a position in CRBP in Q2 2017 and has held it in 30 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • BNP Paribas Financial Markets held 78,120 shares of Corbus Pharmaceuticals worth $733K as of Q2 2026.
  • BNP Paribas Financial Markets bought 67,631 Corbus Pharmaceuticals shares in Q2 2026, an estimated $640K.
  • Corbus Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3523 holding.
  • BNP Paribas Financial Markets first reported a position in Corbus Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.